Imfinzi Approved in the US As First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

AstraZeneca’s Imfinzi in combination with standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.